Drugs / Recombinant human C1 esterase inhibitor
Recombinant human C1 esterase inhibitor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02663687 | Feb → Dec 2016 | hereditary angioedema | Shire | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human C1 esterase inhibitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02663687 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human C1 esterase inhibitor” NCT02663687 ↗ |
| Route | Intravenous | “Subjects will receive escalating doses I-IV as both IV and SC injections” NCT02663687 ↗ |
| Route | Subcutaneous | “Subjects will receive escalating doses I-IV as both IV and SC injections” NCT02663687 ↗ |